Literature DB >> 22795953

New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation.

Giorgos Bamias1, Daniele Corridoni, Theresa T Pizarro, Fabio Cominelli.   

Abstract

In addition to their well-known role in acute injury and chronic inflammation, "innate" cytokines play an important role in health and the maintenance of normal immune homeostasis. This group includes the prototypic cytokines IL-1 and TNFα, as well as several other members belonging to the IL-1 and TNF family, such as IL-18, IL-33, IL-36-38, and TL1A. The dichotomous role of these cytokines has been best characterized in the intestine where innate cytokines may play both a protective and a pro-inflammatory role, depending upon the immmunological status of the host or the type and phase of the inflammatory process. This new information has produced novel pathogenetic hypotheses that have important translational implications both in regard to the prevention and treatment of chronic intestinal inflammation, including Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease. This review will discuss and summarize current data regarding the role of IL-1, TNFα, and their family members in regulating gut mucosal homeostasis and chronic intestinal inflammation.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795953      PMCID: PMC3652608          DOI: 10.1016/j.cyto.2012.06.014

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  101 in total

1.  Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance?

Authors:  Alnoor Ramji; David A Owen; Siegfried R Erb; Charles H Scudamore; Eric M Yoshida
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

3.  Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice.

Authors:  Lihua Duan; Jie Chen; Hongwei Zhang; Heng Yang; Ping Zhu; Ali Xiong; Quansong Xia; Fang Zheng; Zheng Tan; Feili Gong; Min Fang
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

4.  Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.

Authors:  Iván Guerra; Alicia Algaba; José Lázaro Pérez-Calle; María Chaparro; Ignacio Marín-Jiménez; Raquel García-Castellanos; Yago González-Lama; Antonio López-Sanromán; Noemí Manceñido; Pilar Martínez-Montiel; Elvira Quintanilla; Carlos Taxonera; Mónica Villafruela; Alberto Romero-Maté; Pilar López-Serrano; Javier P Gisbert; Fernando Bermejo
Journal:  J Crohns Colitis       Date:  2011-11-13       Impact factor: 9.071

5.  IL-33 attenuates development and perpetuation of chronic intestinal inflammation.

Authors:  Philipp Groβ; Kristina Doser; Werner Falk; Florian Obermeier; Claudia Hofmann
Journal:  Inflamm Bowel Dis       Date:  2012-04-16       Impact factor: 5.325

6.  Distinct inflammatory mechanisms mediate early versus late colitis in mice.

Authors:  David M Spencer; Geertruida M Veldman; Subhashis Banerjee; Joseph Willis; Alan D Levine
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Authors:  Éric Toussirot; Éric Houvenagel; Vincent Goëb; Damien Fouache; Antoine Martin; Philippe Le Dantec; Emmanuelle Dernis; Daniel Wendling; Thiphaine Ansemant; Jean-Marie Berthelot; Brigitte Bader-Meunier; Bernadette Kantelip
Journal:  Joint Bone Spine       Date:  2011-11-15       Impact factor: 4.929

Review 8.  The immunology of mucosal models of inflammation.

Authors:  Warren Strober; Ivan J Fuss; Richard S Blumberg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

9.  Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease.

Authors:  Giorgos Bamias; Garyfallia Kaltsa; Spyros I Siakavellas; Michalis Gizis; George Margantinis; Evanthia Zampeli; Irene Vafiadis-Zoumboulis; Spyros Michopoulos; George L Daikos; Spiros D Ladas
Journal:  Dig Liver Dis       Date:  2011-10-05       Impact factor: 4.088

Review 10.  The impact of the gut microbiota on human health: an integrative view.

Authors:  Jose C Clemente; Luke K Ursell; Laura Wegener Parfrey; Rob Knight
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

View more
  43 in total

Review 1.  Role of type 2 immunity in intestinal inflammation.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Curr Opin Gastroenterol       Date:  2015-11       Impact factor: 3.287

2.  Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis.

Authors:  Roni Nowarski; Ruaidhrí Jackson; Nicola Gagliani; Marcel R de Zoete; Noah W Palm; Will Bailis; Jun Siong Low; Christian C D Harman; Morven Graham; Eran Elinav; Richard A Flavell
Journal:  Cell       Date:  2015-12-03       Impact factor: 41.582

Review 3.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

4.  Protective Role for TWEAK/Fn14 in Regulating Acute Intestinal Inflammation and Colitis-Associated Tumorigenesis.

Authors:  Luca Di Martino; Maneesh Dave; Paola Menghini; Wei Xin; Kristen O Arseneau; Theresa T Pizarro; Fabio Cominelli
Journal:  Cancer Res       Date:  2016-09-09       Impact factor: 12.701

5.  Functional defects in NOD2 signaling in experimental and human Crohn disease.

Authors:  Daniele Corridoni; Kristen O Arseneau; Fabio Cominelli
Journal:  Gut Microbes       Date:  2014-03-05

Review 6.  Immunology of inflammatory bowel disease and molecular targets for biologics.

Authors:  Maneesh Dave; Konstantinos A Papadakis; William A Faubion
Journal:  Gastroenterol Clin North Am       Date:  2014-09       Impact factor: 3.806

7.  MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.

Authors:  QiQi Zhou; Stefan Costinean; Carlo M Croce; Alan R Brasier; Shehzad Merwat; Scott A Larson; Sarpreet Basra; G Nicholas Verne
Journal:  Gastroenterology       Date:  2014-09-30       Impact factor: 22.682

Review 8.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

Review 9.  Inflammatory bowel disease.

Authors:  Daniele Corridoni; Kristen O Arseneau; Fabio Cominelli
Journal:  Immunol Lett       Date:  2014-06-02       Impact factor: 3.685

Review 10.  Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster.

Authors:  Lisa J Wood; Kristianna Weymann
Journal:  Curr Opin Support Palliat Care       Date:  2013-03       Impact factor: 2.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.